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ABSTRACT
Objective: The objective of this work was to formulate, optimize, and characterize ganciclovir (GCV) loaded dry chitosan nanoparticles (CSNPs).
Methods: The GCV loaded CSNPs was prepared by ionic gelation method. Box–Behnken design was employed to optimize the influence of independent 
process and formulation variables like drug to polymer ratio, concentration of sodium tripolyphosphate, and stirring time (min) on the dependent 
variables such as particle size (PS) and drug encapsulation efficiency (% EE). The optimum conditions were determined by regression analysis of the 
output data.
Results: The independent variables had interactive effects and they affected both the responses. The optimum formulation had PS within the range of 
100-120 nm and % EE between 85% and 86%. The prepared GCV loaded CSNPs were dried by fluidized bed drying method. Fourier transform infrared 
spectra showed there was no physicochemical interaction between GCV and CS. Powder X-ray diffraction study showed less intense crystalline peaks 
indicated that GCV may exist in the formulation as amorphous nanodispersion or molecular dispersion form. Differential scanning calorimetry study 
was performed which indicated that the drug was molecularly dispersed inside the matrix of CS. Higuchi model was the best to fit the in vitro release 
data for the GCV loaded CSNPs.
Conclusion: From the results, it can be concluded that the GCV loaded dry CSNPs were formulated, optimized, and characterized using desired 
pharmacotechnical properties.
Keywords: Chitosan nanoparticles, Box–Behnken design, Sodium tripolyphosphate, Ionic gelation.
INTRODUCTION
Polymeric nanoparticles (NPs) have been studied as promising drug 
delivery systems. Different NPs have been formulated and characterized 
with the use of natural as well as synthetic polymers. Based on the 
physicochemical and biological properties, chitosan (CS) a natural 
polymer attracts the researchers to work with Hamidi et al. [1].
CS has been proved to have many other intrinsic properties, such as 
low toxicity (lethal dose 50% in mice is 16 g/kg body weight) [2], 
biocompatibility and biodegradability (Cordova et al., 2008). It is 
mucoadhesive polymer and can increase the residence time at the site of 
absorption and has favorable controlled drug-release abilities [3]. It has 
been demonstrated that CS (when protonated) affects cell permeability 
and enhances paracellular permeability of drugs across the mucosal 
epithelia by opening the intercellular tight junctions.
Ganciclovir (GCV) 9-(1,3-dihydroxy-2-propoxymethyl) guanine, is a 
Biopharmaceutics Classification System Class III drug. GCV (log p = −1.7) 
having molecular weight 255.2 g/mol. It is the first antiviral drug that 
proved to be efficacious in the treatment of Cytomegalovirus (CMV) disease 
in humans [4]. GCV is also used for maintenance therapy and prophylaxis 
of CMV. Oral bioavailability of GCV is ~5%. Possible reasons for the 
poor bioavailability are poor permeability through the gastrointestinal 
tract (GIT) and P-glycoprotein substrate activity [5]. Therefore, it is 
necessary to develop a drug delivery system for GCV which can enhance 
the absorption of GCV. Different drug delivery systems for GCV have been 
developed these days, such as GCV loaded albumin NPs [6], solid lipid 
NPs [7], Long-circulating liposome-encapsulated GCV [8].
This study focus on development of GCV loaded dry CSNPs with an ionic 
gelation method. The 25−2 fractional factorial design was employed to 
screen the process and formulation parameters. Response surface 
methodology with the utilization of Box–Behnken experimental 
design (BBD) was employed for optimization of the particle size 
(PS) and entrapment efficiency (% EE) of GCV loaded dry CSNPs, as 
they are properties of great influence on the pharmacokinetic (i.e., 
biodistribution) and the pharmacodynamic (i.e., therapeutic efficacy) 
of the drug loaded NPs [9]. The optimized formulation was investigated 
for physicochemical characterizations such as scanning electron 
microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), 
and differential scanning calorimetry (DSC) study were employed for 
detection of particle morphology and any physicochemical interaction 
with the CS. In vitro release profile was investigated.
MATERIALS AND METHODS
Materials
GCV was kindly gifted by Bakul Fine Chem Research Center, Mumbai. CS 
(molecular weight=110 kDa, 80.0% degree of deacetylation) was gratis 
sample from Chitopharm S, Norway (USA). Sodium tripolyphosphate (TPP) 
(Cross-linking agent) was purchased from Sigma-Aldrich, Mumbai (India). 
The water used was pretreated with the Milli-Q plus system (Millipore, Q-5 
UVS, India). All other materials of analytical grade were used.
Methods
Preparation of GCV loaded CSNPs
The GCV loaded CSNPs were prepared by ionic gelation method [10]. 
The possible mechanism for ionic gelation is that the ionic interaction 
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between positively charged CS with negatively charged sodium 
TPP [11]. Briefly, CS solutions were prepared by dissolving CS into 
Milli-Q® water at different concentrations containing glacial acetic 
acid (2%). GCV was dissolved in Milli-Q® water containing different 
concentrations of TPP. NPs were formed by adding TPP solution drop 
wise onto a CS solution under mechanical stirring (Remi, India) at room 
temperature. Thereafter, the CS-TPP particle suspension was processed 
under ultrasonication by Probe sonicator (VCX-500, Vibra cell, USA) 
for 5 minutes, producing CSNPs with controlled PS. The prepared GCV 
loaded CSNPs were dried by fluidized bed drying (FBD) method [12]. 
The GCV loaded CSNPs dispersion was centrifuged at 10,000 rpm for 
30 minutes. The sediment was mixed with microcrystalline cellulose 
and Aeroperl R 300 in the ratio of 3:1. The prepared wet mass was 
subjected to FBD at 60-70°C for 4-6 minutes. The dried particles were 
allowed to pass from sieve 40# and further characterized.
Experimental design
From the prior experience and literature survey, the process and 
formulation parameters were identified and screened through 25−2 
fractional factorial design. Eight batches were prepared and evaluated 
for PS, % EE and morphology. Drug:polymer ratio (w/w), concentration 
of TPP (%w/v), stirring time (min), sonication time (min), and stirring 
speed (rpm) were taken as the independent variables while PS (nm), 
EE (%), and morphology were taken as dependent variables for 25−2 
fractional factorial design.
A BBD was used with, three-factors, three-level, and fifteen-runs 
to optimize the preparation conditions. The polynomial equations 
relating factors and responses were obtained by design of experiment 
software® (9.0.6). Table 1 shows the three variables (Drug:polymer 
ratio, concentration of TPP, and stirring time) were represented by A, B, 
and C, respectively. The responses (PS and %EE) were represented by 
Y1 and Y2, respectively [13]. A number of check-point experiments were 
carried out in the optimal area of the BBD to verify the optimization 
procedure validation, as predicted by desirability analysis and by 
comparing the experimental and predicted response.
Characterization
PS determination
The size of the particles was determined by dynamic laser scattering 
technique (Malvern nano S90, Malvern Instruments, UK) PS analyzer at 
temperature of 25°C with an angle of 900.
Entrapment efficiency (% EE)
% EE of the drug was determined by high-performance liquid 
chromatography (HPLC) (LC-2010C HT, Shimadzu, Japan). Formulations 
were centrifuged at 10,000 RPM for 30 minutes. Supernant was 
collected and analyzed for drug content at 254 nm by HPLC (LC-2010C 
HT, Shimadzu, Japan) [14]. The % EE was calculated as follows:
%EE=(Sa−Sb)/Sa*100 (1)
Where, Sa is the total amount of drug in system, Sb is the amount of 
drug in supernant after centrifugation.
Morphology observation
SEM (JSM 6010 LA, JEOL, USA) was used to access the morphology/shape 
of the dried CSNPs. A sample of dried CSNPs was placed on a double 
stick tape over aluminum stubs to get a uniform layer of particles. 
Sample was platinum coated for 20 seconds. Then the sample was 
observed by SEM at 10 kV [15].
FTIR spectroscopy
FTIR spectrum was recorded using NICOLET-6700 (Thermo Scientific, 
USA) to confirm the cross-linking reaction between the phosphoric 
group of the TPP and amino group of CS. The pellet was prepared by 
homogenously dried formulation in dried potassium bromide in a 
mortar and pestle and then powder was compressed under vacuum 
using round flat face punch to produce pellet compact. The sample was 
placed in IR light path and spectra were scanned over the wavelength 
number range of 4000-400 cm−1 [16].
DSC study
DSC study was performed by DSC (DSC-60, Shimadzu Corporation, 
Japan) to characterize the physical state of GCV in CSNPs [17]. The heat 
flow as a function of temperature was measured over a temperature 
range of 50-400°C at heating rate of 10°C/min [18].
In vitro drug release study
In vitro drug release study of GCV loaded CSNPs dispersion, marketed 
formulation (Natclovir: 250 mg Capsule) and drug solution was 
carried out in diffusion cell apparatus (J-FDC-07, Orchid Scientifics 
and Innovations India Pvt., Ltd.) in phosphate buffer pH 6.8. At 
predetermined time intervals, the samples were withdrawn and 
replenish with fresh medium and the absorbance was measured 
by HPLC at 254 nm. Data obtained from the in vitro drug release for 
formulation were fitted to various kinetic models. Each experiment was 
performed in triplicate. The drug release mechanism and linearization 
were determined by finding the goodness of fit (R2) and sum squared of 
residuals (SSR) for each kinetic model [19].
RESULTS AND DISCUSSIONS
The 25−2 fractional factorial design revealed that the drug to polymer 
ratio, concentration of TPP, and stirring time was affected more 
significantly on the PS and % EE. The PS was found to be in the range 
of 112.6±1.1 to 364.9±4.759 nm and % EE in the range of 10±5.4 to 
83.57±1.4% with spherical shape.
Model fitting by BBD
The screening design suggested that drug to polymer ratio, 
concentration of TPP, and stirring time were most significant factors. 
These significant factors were further optimized through the BBD. 
The measured significant variables range between 121.20±2.7 and 
294.5±15.4 nm for PS and between 59.95±0.5 and 85.15±1.1 for % EE. 
These indicated that PS and % EE of the prepared CSNPs were largely 
influenced by the selected variables. The polynomial equations for both 
responses were as follows:
Y1=+121.53−17.54A (p<0.05)−0.13B (p<0.05)−4.39C (p>0.05)−11.79 
AB (p<0.05) −9AC (p<0.05)+19.93BC (p<0.05)+86.16A2 
(p>0.05)+40.18B2 (p>0.05) −66.06C2 (p>0.05) (2)
Y2=+84.02−0.47A (p<0.05)+2.55B (p<0.05) −0.53 C (p<0.05) 
+3.58AB (p<0.05)− 3.23AC (p<0.05)−2.78BC (p>0.05)−12.11A2 
(p>0.05)−5.98B2 (p>0.05)+0.085C2 (p>0.05)  (3)
Where, Y1 is the PS, Y2 is the % EE. A, B, and C is drug:polymer ratio, 
concentration of TPP and stirring time, respectively. AB, AC, and BC are 
the interaction terms which show how the responses change when two 
variables are concurrently changed, while the effect of changes in each 
single variable on the response is reflected by A, B, and C the main effect 
terms and A2, B2, and C2 the quadratic terms. Table 2 presents the results 
of which the analysis of variance (ANOVA) was conducted to test the 
Table 1: Variables with their coded and actual values for BBD
Independent variables Low Medium High
Coded values (−1) (0) (1)
A=Drug: Polymer ratio (w:w) 1:2 1:3 1:4
B=Concentration of TPP (%w/v) 0.3 0.4 0.5
C=Stirring time (min) 50 100 150
Dependent variables constrains
Y1=Particle size (nm) 100-200 nm
Y2=EE (%) Maximum
EE: Entrapment efficiency, BBD: Box–Behnken experimental design
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quadratic models significance and the lack of fit for the experimental 
data.
Equations (2) and (3) show the effect of the independent variables on 
the PS and % EE. As A, B, and C the three independent variables changed 
simultaneously, the coefficient of interaction of Y1 and Y2 also changed. 
There is increase in the PS due to increase in the concentration of TPP 
would be due to cross-linkage between TPP and CS. As there is increase 
in the concentration of TPP, there would be more tripolyphosphoric 
ions to cross-link with amino groups on CS chains. As stirring time 
increases, there is increase in the PS. This may be due to aggregation 
of particles [20].
There is decrease in the % EE with increase in the drug:polymer ratio. 
This may be due to the fact that at higher concentration CS molecules in 
the dispersion are present very close to each other during precipitation 
by polyanion. Hence, they got precipitated to form a large particle and 
this larger particle is having low entrapment of drug [20].
To check the significance of the quadratic models and the lack of 
fit for the experimental data the ANOVA was conducted (Table 2). 
Fischer’s ratio (F) confirms the models significances, where FY1=9.71 
(p=0.011<0.05) and FY2=5.93 (p=0.032<0.05). The value of correlation 
coefficient (R2) for equation was found to be R12=0.961 and R22=0.934, 
indicating a good fit.
The Student’s t-test was applied to determine the significant difference 
between actual and predicted value of dependent parameters. The 
p-value for the PS and % EE was found to be 0.372 and 0.468, respectively, 
which showed that at 5% level of significance, there is no significant 
difference between actual and predicted values of PS and % EE.
Fig. 1 shows the three-dimensional response surface plots of 
independent variables interactive effects on the PS and % EE. Optimum 
conditions for preparation of CSNPs can be achieved for different values 
of independent variables within the experimental range, followed by 
desirability function. At optimized conditions, GCV loaded CSNPs had 
the PS 121.20±2.7 nm and % EE of 85.15±1.1% with the desirability 
of 0.978 (Fig. 2). There was no significant difference between the 
predicted and actual values of the measured responses as the p>0.05. 
Fig. 3 shows overlay contour plot of the location of the desirable region 
for selection of optimized NP formulation of GCV.
Morphology observation
SEM micrographs are shown in Fig. 4 which revealed that prepared 
particles were spherical in shape which is favorable for the uptake 
through the GIT.
FTIR study
In the FTIR spectra of cross-linked CS (Fig. 5), the peak of 1655 cm-1 
disappeared and two new peaks at 1645 cm-1 and 1554 cm-1 appeared. 
The disappearance of the band could be attributed to the linkage 
between the phosphoric and ammonium ions. The cross-linked CS also 
showed a peak for P=O at 1155 cm-1 [21]. Cross-linked CS-TPP in the 
NPs also shows broader peak at 2934-3421 cm-1 indicates hydrogen 
bonding between OH and NH2 groups [22]. Hence, this confirms the 
cross-linking between CS and TPP.
DSC study
DSC studies (Fig. 6) were performed to understand the behavior of 
the cross-linked CS on application of thermal energy. Polysaccharides 
usually have a strong affinity for water, and in solid state, these 
macromolecules may have disordered structures that can be easily 
hydrated. The endotherm related to evaporation of water is expected to 
reflect the molecular changes brought in after cross-linking.
The thermogram of CS showed endotherm at 102.36°C with the 
enthalpy of fusion (ΔH) 81.93 J/g. The water-holding capacity of cross-
linked CS with TPP was found to be more (ΔH 244.24 J/g) compared 
with that of plain CS. The cross-linking of CS with TPP at different pH 
modifies the crystalline nature of CS. The hydrophilicity of cross-linked 
CS is higher at pH 3, which might be responsible for its increase in the 
water holding capacity. On the basis of these results, it can be stated 
that increase in the polar groups and reduction in crystalline domains 
caused an increase in the water-holding capacity of cross-linked CS. 
These results are in agreement with the work done by Kittur [23]. 
An endothermic melting peak of GCV was observed at 253.88°C. The 
absence of this peak in the thermogram of formulation indicates that 
the drug was molecularly dispersed inside the matrix of CS as a solid 
solution.
Table 2: ANOVA analysis for measured responses
Response Source dfa SSb MSc F ratiod p value
Y1 Model 9 48816.51 5424.06 9.71 0.111
Error 5 2794.25 558.85 - -
Total 14 51610.76 - - -
Y2 Model 9 823.00 91.44 5.93 0.0321
Error 5 77.10 15.42 - -
Total 14 900.10 - - -
aDegree of freedom, bSum of square, cMean sum of square, dModel MS/error MS, 
ANOVA: Analysis of variance
Fig. 1: Three-dimensional response surface curves for particle size
298
Asian J Pharm Clin Res, Vol 10, Issue 3, 2017, 295-299
 Patel et al. 
Fig. 2: Three-dimensional response surface curves for % entrapment efficiency
Fig. 3: Overlay contour plot showing the location of the desirable 
region for selection of optimized nanoparticle formulation of 
ganciclovir
Fig. 4: Scanning electron microscopy micrograph of ganciclovir 
loaded chitosan nanoparticles
Fig. 5: Fourier transform infrared spectra of (a) Chitosan, 
(b) ganciclovir (GCV), (c) GCV loaded chitosan nanoparticles
Fig. 6: The overlay differential scanning calorimetry thermogram 
of ganciclovir (GCV) and GCV loaded chitosan nanoparticles 
(CSNPs) (fluidized bed drying CSNPs)
In vitro drug release study
The in vitro drug release study of GCV loaded CSNPs, marketed 
formulation and drug solution was carried out in pH 6.8 phosphate 
buffer. Drug exhibited sustained release behavior up to the 24 hrs. 
Drug release was found up to 71.63±0.36%, 45.36±1.96%, and 
27.23±1.19% in GCV loaded CSNPs, marketed formulation and drug 
solution, respectively, at the end of 24 hrs. It was noteworthy that 
formulation showed an initial burst release possibly due to the small 
size of the NPs. As the particle diameter was reduced, the specific 
surface area increased, while the path length to the surface of the drug 
decreased [24]. In the comparison with the marketed formulation the 
prepared GCV loaded CSNPs released drug in higher amount. The 
model having highest value of R2 and lowest value of SSR is considered 
as the best model to fit [25]. From the results, it was found that drug 
release from CSNPs follows Higuchi model (R2=0.9078; SSR=0.3796) 
indicating that drug release as a diffusion process based on the Fick’s 
law [18].
CONCLUSION
In the presented research, the process and formulation parameters 
were optimized through the BBD. The variables drug to polymer 
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ratio, concentration of TPP, and stirring time affected the PS and % 
EE more significantly. The GCV loaded dry CSNPs showed diffusion 
controlled release mechanism up to 24 hrs along with ease of 
formulation.
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